1-13 of 13
Hugo Fernandez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Free
Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem Solh, Uday Popat, Michele Donato, Luis Pineiro, Hugo Fernandez, Saar Gill, Anson Snow, Joseph Uberti, Timothy White, Yun Wang, Cuong Nguyen, Chrystal Louis, Shrikanta Chattopadhyay, Michelle Matzko, Ran Reshef
Journal: Blood
Blood (2025) 146 (Supplement 1): 2391.
https://doi.org/10.1182/blood-2025-2391
Published: 2025
Journal Articles

Racial and socioeconomic disparities in smoldering multiple myeloma: Insights from the surveillance, epidemiology, and end Results (SEER) database.

Free
Imran Khan, Mohammad Ebad Ur Rehman, Samra Sohail, Shahzaib Maqbool, Abat Khan, Adil Khan, Pouyan Gohari, Hugo Fernandez, Nina T Nguyen
Journal: Blood
Blood (2025) 146 (Supplement 1): 2252.
https://doi.org/10.1182/blood-2025-2252
Published: 2025
Journal Articles

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials

Free
Douglas Tremblay, Li Chen, Zhuoxin Sun, Chezi Ganzel, Hugo Fernandez, James Foran, Daniel Arber, Hillard Lazarus, Yanming Zhang, Elisabeth Paietta, John Bennett, Jacob Rowe, Mark Litzow, Martin Tallman, Ehab Atallah, Selina Luger
Journal: Blood
Blood (2025) 146 (Supplement 1): 871.
https://doi.org/10.1182/blood-2025-871
Published: 2025
Journal Articles

Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles

Free
Shella Saint Fleur-Lominy, Li Chen, Zhuoxin Sun, Francine Garrett-Bakelman, Mihir Shukla, Hugo Fernandez, James Foran, Larry Cripe, Hillard Lazarus, Peter Wiernik, Jacob Rowe, Martin Tallman, Mark Litzow, Yanming Zhang, Selina Luger, Irum Khan
Journal: Blood
Blood (2025) 146 (Supplement 1): 290.
https://doi.org/10.1182/blood-2025-290
Published: 2025
Journal Articles

Efficacy and safety of venetoclax in high-risk Relapsed/Refractory AL amyloidosis: A systematic review and meta-analysis

Free
Muhammad Atif Khan, Abat Khan, Umar Akram, Rameesha Mehreen, Faiza Humayun Khan, Claudia E Paba Prada, Nina T Nguyen, Hugo Fernandez
Journal: Blood
Blood (2025) 146 (Supplement 1): 5747.
https://doi.org/10.1182/blood-2025-5747
Published: 2025
Journal Articles

Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.

Free
Timour Baslan, Pascal Belleau, Astrid Deschênes, Yanming Zhang, Zhuoxin Sun, Francine Garrett-Bakelman, Maria Kleppe, Elisabeth Paietta, Larry Cripe, Hugo Fernandez, Martin Tallman, Jacob Rowe, Hillard Lazarus, Ari Melnick, Mark Litzow, Ross Levine, Nevenka Dimitrova, Selina Luger, Alexander Krasnitz, Scott Lowe
Journal: Blood
Blood (2025) 146 (Supplement 1): 5263.
https://doi.org/10.1182/blood-2025-5263
Published: 2025
Journal Articles

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Free
Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem Solh, Uday Popat, Michele Donato, Luis Pineiro, Hugo Fernandez, Saar Gill, Anson Snow, Joseph Uberti, Sameem Abedin, Mahasweta Gooptu, Mathew Angelos, Jeremy Pantin, Kwang Woo Ahn, Ramola Bhandarkar, Shrikanta Chattopadhyay, Samantha Jaglowski, Chrystal Louis, Michelle Matzko, Leavitt Morrison, Waleska Pérez, Eugene Poggio, Ran Reshef
Journal: Blood
Blood (2025) 146 (Supplement 1): 2400.
https://doi.org/10.1182/blood-2025-2400
Published: 2025
Journal Articles

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

Free
Clinical Trials & Observations
Mithat Gönen, Zhuoxin Sun, Maria E. Figueroa, Jay P. Patel, Omar Abdel-Wahab, Janis Racevskis, Rhett P. Ketterling, Hugo Fernandez, Jacob M. Rowe, Martin S. Tallman, Ari Melnick, Ross L. Levine, Elisabeth Paietta
Journal: Blood
Blood (2012) 120 (11): 2297–2306.
https://doi.org/10.1182/blood-2012-02-414425
Published: 2012
Includes: Supplemental data
Journal Articles

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

Free
Janelle Perkins, PharmD, Jongphil Kim, PhD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD, Ernesto Ayala, MD, Lia Perez, MD, Hugo Fernandez, MD, Karen Fancher, PharmD, Cheryl Tate, PharmD, Teresa Field, MD
Journal: Blood
Blood (2009) 114 (22): 3347.
https://doi.org/10.1182/blood.V114.22.3347.3347
Published: 2009
Journal Articles

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Free
Maria E. Figueroa, Lucy Skrabanek, Yushan Li, Anchalee Jiemjit, Tamer E. Fandy, Elisabeth Paietta, Hugo Fernandez, Martin S. Tallman, John M. Greally, Hetty Carraway, Jonathan D. Licht, Steven D. Gore, Ari Melnick
Journal: Blood
Blood (2009) 114 (16): 3448–3458.
https://doi.org/10.1182/blood-2009-01-200519
Published: 2009
Includes: Supplemental data
Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine.

Free
Teresa Field, MD, PhD, Melissa Alsina, MD, Ernesto Ayala, MD, Hugo Fernandez, MD, William Janssen, PhD, Mohammed Karfan-Dabaja, MD, Jeffery Lancet, MD, Mafda Melchert, MD, Jyoti Raychaudhuri, MD, Daniel Sullivan, MD, Alan List, MD, Claudio Anasetti, MD, William Poling, PhD, Janelle Perkins, PharmD
Journal: Blood
Blood (2007) 110 (11): 5035.
https://doi.org/10.1182/blood.V110.11.5035.5035
Published: 2007
Journal Articles

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Free
Todd Alekshun, MD, Christine Mcisaac-Simonelli, RN, Mohamed Kharfan-Dabaja, MD, William Dalton, MD, PhD, Benjamin Djulbegovic, MD, Hugo Fernandez, MD, Daniel M. Sullivan, MD, Ernesto Ayala, MD, Teresa L. Field, MD, Dawn Garrett, LPN, William E. Janssen, PhD, Beth Maddox, RN, Lia Perez, MD, Dawn Kettner, PA, Janelle Perkins, PharmD, Jyoti Raychaudhuri, MD, Claudio Anasetii, MD, Melissa Alsina, MD
Journal: Blood
Blood (2007) 110 (11): 5131.
https://doi.org/10.1182/blood.V110.11.5131.5131
Published: 2007
Journal Articles

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Free
Daniel Sullivan, MD, Melissa Alsina, MD, Claudio Anasetti, MD, Teresa Field, MD, PhD, Mohamed Kharfan-Dabaja, MD, Hugo Fernandez, MD, William Dalton, PhD, MD, Ernesto Ayala, MD, Jyoti Raychaudhuri, MD, Lia Perez, MD, Janelle Perkins, PharmD, Michael Schell, PhD, Christine McIsaac, RN, Beth Maddox, RN, Jana Gump, BS, Richard Lush, PhD, Tony Frudakis, PhD
Journal: Blood
Blood (2007) 110 (11): 943.
https://doi.org/10.1182/blood.V110.11.943.943
Published: 2007